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ABSTRAK  
Glaukoma merupakan antara penyakit mata yang menjadi penyebab utama kebutaan, 
dengan separuh daripada kes glaukoma di seluruh dunia terdiri daripada masyarakat 
Asia. Glaukoma primer sudut tertutup (GPST) merupakan penyakit yang lazim di 
dapati di kalangan penduduk Asia. Terdapat variasi dari segi prevalens GPST 
mengikut bangsa di Asia. Bangsa Melayu dikenalpasti menghidapi GPST dengan 
prevalens sebanyak 0.12% hingga 2.5%. GPST pada masyarakat Asia didapati lebih 
agresif dan progres dengan kadar yang cepat berbanding masyarakat Eropah. Ini 
menyebabkan kadar kebutaan yang tinggi dalam kalangan penduduk Asia. 
Mengenalpasti penanda genetik yang berkecenderungan kepada progres penyakit 
GPST adalah penting untuk mencegah kebutaan dan penemuan baru rawatan pada 
masa akan datang.  
 
OBJEKTIF 
Kajian ini bertujuan untuk mengenalpasti perkaitan di antara tiga penanda genetik iaitu 
PLEKHA7, ABCC5 dan KALRN dengan progres penyakit GPST di kalangan pesakit 
Melayu.  
 
METODOLOGI 
Kajian rentas melibatkan 163 orang pesakit GPST dari Hospital Universiti Sains 
Malaysia dan Hospital Raja Perempuan Zainab II telah dijalankan di antara April 2015 
hingga April 2017. Darah vena sebanyak 6 ml diambil dari semua pesakit. 
Pengekstrakan DNA telah dijalankan menggunakan kit pengekstrakan DNA komersil 
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(QIAGEN, Germany). Pengoptimuman primer dijalankan ke atas rs11024102 gen 
PLEKHA7, rs17217796 gen ABCC5 dan rs1392912 gen KALRN. Reaksi berantai 
polimerase (PCR) dijalankan dan diikuti oleh pembersihan amplikon. Polimorphisme 
nukleotida tunggal (SNP) dikenalpasti melalui proses penjujukan DNA. Medan ujian 
penglihatan menggunakan Humphrey Visual Field (HVF) dijalankan semasa calon 
pesakit di pilih. Perubahan medan penglihatan dibandingkan dengan hasil ujian semasa 
pertama kali diagnosa dibuat. Berdasarkan persetujuan diantara dua sistem skor ke atas 
ujian medan penglihtan; Advanced Glaucoma Intervention Study (AGIS) dan Hodapp-
Parrish- Anderson (HPA), pesakit dibahagikan kepada kumpulan yang progres dan 
tidak progres.   Ujian statistik ‘Chi-Square’ digunakan untuk menganalisa perkaitan di 
antara penanda aras genetik dan progres penyakit GPST.  
 
KEPUTUSAN 
163 orang pesakit berbangsa Melayu dengan GPST direkrut dalam kajian ini (58 orang 
lelaki dan 105 orang perempuan). Keputusan kajian mendapati bahawa 29 (18%) orang 
pesakit didapati menunjuk penyakit yang progresif setelah di rawat selama 6 tahun 
(SD 1.0) tahun.  Kekerapan allele minor (MAF) untuk PLEKHA7 rs11024102 (G/A), 
ABCC5 rs17217796 (C/G) dan KALRN rs1392912 (A/G) adalah 0.44, 0.08 and 0.48 
masing-masing. Tiada pebezaan yang signifikan terhadap kekerapan alele rs11024102 
(p=0.828), rs17217796 (p=0.865) dan rs1392912 (p=0.684) diantara pesakit GPST 
yang progres dan tidak progres.  
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KESIMPULAN 
Kajian ini mendapati walaupun penanda aras genetik PLEKHA7 dan ABCC5 
mempunyai perkaitan dengan risiko GPST, namun tidak mempengaruhi progres GPST 
pada pesakit berbangsa Melayu. Kajian ini juga menunjukkan KALRN gene tidak 
mempengaruhi progres GPST. Berkemungkinan terdapat penanda aras genetik yang 
lain yang lebih cenderung kepada progres GPST.  
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ABSTRACT 
INTRODUCTION  
Glaucoma is the leading cause of irreversible blindness worldwide, with Asians 
accounting for approximately half of the world’s glaucoma cases. Primary angle 
closure glaucoma (PACG) is highly prevalence among Asians. The prevalence of 
PACG varies widely according to the different races in Asia. PACG prevalence in 
Malays ranges from 0.12% to 2.5%. Asians patients with PACG are found to progress 
faster than Caucasians. PACG is responsible for more blindness in Asian population. 
Identifying the potential susceptible genetic markers for progression of PACG in 
Malays is essential for management strategy to prevent blindness and future 
development of new treatment.  
 
OBJECTIVE  
To determine association of genetic markers of PLEKHA7, ABCC5 and KALRN and 
progression in PACG Malay patients. 
 
METHODOLOGY  
A cross sectional study was conducted between April 2015 and April 2017 involving 
Malay patients with PACG from Hospital Universiti Sains Malaysia and Hospital Raja 
Perempuan Zainab II (Kota Bharu). Venesection was performed. DNA extraction was 
conducted using commercialize DNA extraction kit (QIAGEN, Germany). 
Optimization of primer was conducted for rs11024102 of PLEKHA7, rs17217796 of 
ABCC5 and rs1392912 of KALRN. Polymerase chain reaction (PCR) was carried out 
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using Thermocycler SureCycler 8800 (Agilent Technologies, Santa Clara, CA). PCR 
products were purified using Illustra Exostar (Ge Healthcare Bio-Science) PCR 
product purification kit. PCR products were sent to a private laboratory (First Base 
laboratories, Selangor, Malaysia) for cycle sequencing. Humphrey visual fields (HVF) 
were conducted during study recruitment. HVF obtained were compared with two 
baseline visual field. Patients were grouped into progress and non-progress based on 
the agreement of both AGIS and Hodapp-Parrish scoring system on HVF. Chi Square 
test was used to analyse association of genetic markers and progression of PACG.  
 
RESULTS 
A total of 163 Malay patients were recruited with PACG primary (58 men and 105 
women). Forty nine or approximately 30% of patients had acute primary angle closure 
attack. There were 29 (18%) patients with visual field progression of PACG after a 
mean follow up of 6.0 (SD 1.0) years. Minor allele frequency (MAF) for PLEKHA7 
rs11024102 (G/A), ABCC5 rs17217796 (C/G) and KALRN rs1392912 (A/G) is 0.44, 
0.08 and 0.48 respectively. There was no statistically significant association between 
rs11024102 (p=0.828), rs17217796 (p=0.865) and rs1392912 (p=0.684) with 
progression of PACG in Malay patients.  
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CONCLUSION  
 
Although genetic markers of PLEKHA7 and ABCC5 were found to associate with the 
risk of PACG but they have no role on progression of PACG in Malay population. In 
this study, KALRN gene did not show any role on progression of PACG in Malay 
population. Perhaps, there are other susceptible genetic markers responsible for 
progression in PACG.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                              
 
 
 
 
 
Chapter 1 
Introduction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                              
 
1.1 GLAUCOMA 
Glaucoma is a disease that has been described in literature as early as 400BC, where 
the term “glaukos” means blue, green and cloudy. British oculist Richard Banister 
described it as the firmness of the eye, however in the 18th and 19th century it was 
thought to be a disease of the vitreous humour, arthritis and iritis. This was disapproved 
by Helmholtz in 1851 who noted that the vitreous was normal but the optic nerve was 
cupped. Curran put forth the pupillary block theory in 1920s (Curran, 1920). Not long 
after this, the gonioscope was invented by Trantas, Salzmann and Koeppe (Consoli et 
al., 2005). 
Glaucoma is a group of chronic progressive optic neuropathies comprising of a slow 
progressive degeneration of the retinal ganglion cells and their axons, resulting in 
structural changes of the optic disc and a corresponding pattern of visual field loss 
(Weinreb and Khaw, 2004). It is a complicated disease with many underlying 
mechanisms and a complex relationship with intraocular pressure (IOP). In 2000, The 
Advanced Glaucoma Intervention Study showed the importance of IOP in glaucoma 
progression (Investigators, 2000). This study found that patients with IOPs of 
<18mmHg (average, 12.3mmHg) were unlikely to have visual field progression. This 
study confirmed that having good IOP control will slow disease progression. 
Glaucoma can be classified into two main groups according to the angle structure; 
closed angle glaucoma and open angle glaucoma (Coleman, 1999). Open and closed 
angle glaucoma can further be classified into primary or secondary glaucoma. Primary 
glaucoma of open angle category includes primary open angle glaucoma (POAG), 
juvenile open angle glaucoma (JOAG), normal tension glaucoma (NTG) and 
congenital glaucoma (Foster, 2002). The most common type may differ from one 
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region of the world to another. For instance, primary angle closure glaucoma (PACG) 
is more prevalent in certain regions in Asia, whereas POAG is more equally distributed 
throughout the world and is the most common form of the disease, accounting for 74% 
of all glaucoma cases (Quigley & Broman, 2006). 
 
1.2 PRIMARY ANGLE-CLOSURE GLAUCOMA 
Acute angle closure glaucoma is diagnosed when there is an occurrence of a congestive 
episode with headache, blurring of vision, halos around the light with associated eye 
redness and pain and the presence of markedly raised IOP in an eye with shallow 
anterior chamber, vertically oval pupil, corneal edema and gonioscopically closed 
angle (Foster et al., 2002). Chronic angle closure glaucoma (CACG) represents 
chronically elevated IOP, in association with an angle in which at least 180° of 
trabecular meshwork was not visible on gonioscopically, confirmed peripheral anterior 
synechiae which is irreversible, optic nerve head and visual field changes with or 
without prior symptoms (Foster and Johnson, 2000). In a study done in India, Sihota 
et al (2011) reported that 80% of primary angle closure glaucoma is asymptomatic. 
Many studies have shown similar observation, thus it was coined “sneak thief” due to 
almost asymptomatic course until the very advanced stage of the disease (Ichhpujani 
et al., 2010; Liza-Sharmini et al., 2014). 
 
1.2.1 Global prevalence of PACG  
Previously, the estimated global mean prevalence for OAG in 2010 was 1.96% while 
ACG was 0.69% (Quigley & Broman, 2006). However, based on the results obtained 
from latest systemic review and meta-analysis, showed that the overall prevalence of 
glaucoma for the population aged 40 to 80 years was 3.54% of which 3.05% was 
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attributed by POAG and 0.50% by PACG in 2013 (Tham et al., 2014). The analysis 
also stated that the number of people (aged 40-80 years) with glaucoma may increase 
from 64.3 million (2013) to 76.0 million in 2020 and 111.8 million in 2040. The 
prevalence of PACG varied across geographic regions with the highest prevalence of 
PACG being Asia (1.09%; 95% CI, 0.43-2.32) (Tham et al, 2014). The prevalence of 
POAG has always been higher than PACG in the western world (Klein et al., 1992; 
Mitchell et al., 1996).  
 
However, in 2012, European based study concluded that PACG is more common than 
previously thought. Their result showed 130 000 people in the UK, 1.60 million people 
in Europe and 581 000 people in the USA with PACG in 2012. They predicted cases 
will increase by 19% in UK, 9% in Europe and 18% in USA within the next decade, 
on account of ageing (Day et al., 2012). Asia constitutes for a disproportionately higher 
prevalence of PACG as opposed to the prevalence of POAG cases which are more 
evenly distributed throughout the world (Quigley, 1996). In 2010, higher prevalence 
of PACG cases were seen in Asian countries; China 1.26%, Southeast Asia 1.20%, 
India 0.80%, as compared to the lower prevalence seen in other parts of the world; 
Europe 0.25%, Latin America 0.19%, Africa 0.16%. Japan and the Middle East 
registered lower than average prevalence of PACG; 0.39% and 0.16% respectively 
(Quigley & Broman, 2006). Therefore, Asians represent 87% of the 15.7 million with 
ACG (Quigley & Broman, 2006). 
 
1.2.2 Prevalence of PACG in South East Asia 
There are variations in glaucoma prevalence across ethnicity and Asians had the 
highest prevalence of PACG (1.20%; 95% CI, 0.46-2.55) than it is in Africans or 
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Europeans and is a significant cause of visual morbidity in East Asia (Congdon et al., 
1992; Foster et al., 1996; Foster et al., 2000). 
 
Studies conducted in southern states of India have shown a varied prevalence of PACG 
between 0.5% to 4.3% (Dandona et al., 2000; Ramakrishnan et al., 2003; Vijaya et al., 
2006). Various epidemiologic population-based studies in East Asia and Southeast 
Asia shows variation in the prevalence according to different parts of Asia; Chinese 
1.3% (He et al., 2006), Mongol 1.4%( Foster et al., 1996), Thai 0.9% (Bourne et al., 
2003). The Meiktila Eye study in rural Myanmar showed the prevalence of glaucoma 
in the population aged ≥40 years in rural, central Myanmar was 4.9%. The ratio of 
PACG to POAG was approximately 1.25:1 (Casson et al., 2007). Malays are among 
affected races in South East Asian with PACG prevalence of 0.12% to 2.5% (Bourne, 
2003; Casson et al., 2007; Shen et al., 2008). 
 
1.3 GLAUCOMA PROGRESSION AND SEVERITY 
Glaucoma is a chronic progressive disease. Traditionally, the diagnosis of glaucoma 
was based on three criteria: an increased in IOP, typical visual field defects, and 
characteristic optic disc damage. However, IOP value alone can neither be used to 
distinguish healthy from affected individuals nor to stage the disease according to its 
severity, due to its poor sensitivity and specificity (Brusini and Johnson, 2007). The 
disease causes damages to ganglion cell and its respective axons as well, resulting in 
progressive and asymmetric changes in the optic cup, with corresponding visual field 
loss. Often visual field changes are preceded by structural changes, about 40% retinal 
nerve fibre death occurs before detectable visual field changes (Tuulonen and 
Airaksinen, 1991). Therefore, glaucomatous damage can be quantified using either 
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structural (changes in the optic nerve and retinal nerve fibre layer) or functional loss 
(visual field defects), or a combination of both (Brusini and Johnson, 2007; Medeiros 
et al., 2012). The rate of progression varies highly among patients (Leske, 2007; 
Rossetti et al., 2010). Disease progression in glaucoma is common and despite 
treatment, the majority of patients still progress (Rossetti et al., 2010). 
 
1.3.1 Evaluation of visual field progression 
Detection of progression plays an important role in the clinical diagnosis and 
management of glaucoma. Standard automated perimetry (SAP) remains the method 
of choice for monitoring functional changes in the disease. Various studies have 
chosen visual field outcome as an end point (Schulzer, 1994; Katz et al., 1999; Keltner 
et al., 2000; Heijl et al., 2008). The evaluation of visual field progression can be 
achieved by employing trend analysis and event-based analysis (Birch et al, 1995; 
Heijl et al, 2002; Spry and Johnson, 2002; Diaz-Aleman et al, 2009).  
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Table 1.3 Examples of event and trend base analysis  
 
 
 
 
    
 
 
  
Event based analysis Trend based analysis 
Advanced glaucoma intervention study 
criteria 
Linear regression analysis 
Collaborative initial glaucoma treatment 
study  
Guided progression analysis 
Hodapp-Parish-Anderson criteria Statpac 
Mill’s staging system Statpac 2 
Early manifest glaucoma treatment study 
criteria 
Progressor  
Glaucoma progression analysis 1  
Glaucoma progression analysis 2  
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1.3.1.1 Trend base analysis  
Trend analysis uses mean deviation index (MDI) or visual field index (VFI) calculated 
from the Humphrey visual field (HVF) perimetry. It has become a standard index for 
estimating the progression rate of glaucoma (Casas-Llera et al., 2009). Nonetheless, 
MDI calculation can be influenced by the presence of cataract correlate poorly with 
clinical findings. Thus, progressive increase in cataract density can falsely be mistaken 
as high glaucoma progression rate (Heijl et al, 1986; Klein et al, 1996; Koucheki et al, 
2004). The value of MDI will improve after cataract extraction and this may further 
interfere with the evaluation and monitoring of glaucoma progression (Klein et al, 
1996, Koucheki et al, 2004). Another limitation of using MDI is that it is very weakly 
centre weighted, therefore it does not correlate well to patient’s real visual function 
(Heijl et al, 1986). 
 
1.3.1.2 Event-based Analysis 
The event-based analysis is essential to detect whether progression has occurred or not 
(Caprioli, 2008). The are many examples of standard automated perimetry methods to 
detect progression (Hodapp et al., 1993). AGIS investigators developed scoring 
system; 0 (no defect) to 20 (all test sites deeply depressed). Visual field considered 
progress if there’s a worsening of 4 units in the AGIS score sustained during 3 
consecutive 6-month visits (Investigators, 1994). 
 
Mills and colleagues had proposed a staging system by upgrading Hodapp-Parish-
Anderson criteria (Mills et al., 2006). There are three factors on categorising of stages; 
stages 0 and 1 depends on pattern standard deviation (PSD) and hemifield test results, 
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stages 2 through 4 are adjusted by numeric (dB) plot, and the pattern deviation plot is 
used for 1 through 4. Stage 5 classifications are on the basis of poor visual acuity and 
inability to perform visual field testing as a result of a severe loss of vision. Progression 
was considered when visual field progress from one stage to the next (Mills et al., 
2006). 
 
Glaucoma progression analysis (GPA) software incorporated in Humphrey Visual 
Field Analyser (HVA) (Carl-Zeiss Meditec, Dublin, CA) is an example of event-based 
analysis (Casas-Llera et al., 2009). The software will give an analysis of pattern 
standard deviation values (Casas-Llera et al., 2009) allowing for glaucoma progression 
monitoring. Recently, glaucoma progression index (GPI) was introduced to measure 
the rate of VF progression (Bengtsson et al., 2009). It was found that GPI analysis is 
more accurate than the traditional MDI analysis for determining the rate of progression 
and is considerably less affected by cataract or cataract surgery (Bengtsson and Heijl, 
2008). 
 
The event-based GPA analysis is capable of detecting progression earlier compared to 
trend VFI analysis by 7 months (Casas-Llera et al., 2009). Trend-based analysis 
requires a larger number of HVF test to detect progression (Caprioli, 2008). An 
innovative study combining both event and trend based analysis by building a 
hierarchical Bayesian model was done by Medeiros and colleagues in which it shows 
promising reliability in measuring visual field progression outcome (Casas-Llera et 
al., 2009).  
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1.3.2 Evaluation of structural progression 
The progression of glaucoma can also be monitored by the structural changes of the 
optic nerve head (ONH). According to these studies; collaborative initial glaucoma 
treatment study (CIGTS) and ocular hypertension treatment study (OHTS), structural 
damage may be a more sensitive indicator of glaucomatous progression than functional 
damage in patients with glaucoma or ocular hypertension (OHT) (Kass et al., 2002). 
With the advancement of technology, newer and more sophisticated ophthalmic 
imaging devices have been introduced such as Heidelberg retinal tomograph (HRT) 
and optical coherence tomograph (OCT). These non-invasive imaging tools provide 
us with quantitative images and allow for precise observation, documentation and 
monitoring of the optic nerve head , retinal nerve fibre layer  and inner macular layer 
(Medeiros et al., 2009; Bussel et al., 2013). However, some authors recommended 
determining progression on the agreement and correspondence between structural 
progression and functional deterioration (Leung et al., 2010; Medeiros et al., 2011).  
 
1.3.3 Staging and severity 
1.3.3.1 Advanced Glaucoma Intervention Study (AGIS) 
A continuous glaucoma staging systems have been recommended by the Advanced 
Glaucoma Intervention Study. In this scoring system, the severity of glaucoma can be 
quantified using the Humphrey 24-2 threshold test. The AGIS visual field defect score 
is based on the number and depth of clusters of adjacent depressed test sites in the 
upper hemifield, lower hemifield and in the nasal area of the total deviation plot (an 
event-based analysis) (Investigators AGIS, 1994; Ng et al, 2012). The scores for each 
hemifield and nasal area are summed up and visual field scores are divided into five 
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categories: 0 = normal visual field; 1-5 = mild damage; 6-11 = moderate damage; 12-
17 = severe damage; and 18-20 = end stage (Investigators, 1994). This staging system 
is almost accurate and provides standardised classification of visual field according to 
severity. Thus, it is very useful for scientific and clinical research. However, it is time-
consuming, requires special training and not practical for day-to-day clinical usage 
(Brusini and Johnson, 2007). 
 
1.3.3.2 Hodapp-Parish-Anderson (HPA) 
HPA classification system considers two criteria: the first criterion is the overall extent 
of damage using both the mean deviation (MD) value and the number of defective 
points in the Humphrey Statpac-2 pattern deviation probability map of the 24-2, SITA-
STANDARD test; the second is based on the defect(s) proximity to the fixation point 
(Hodapp et al., 1993; Susanna Jr and Vessani, 2009). This classification, though 
popular has its own disadvantages, namely the visual field defect is characterised into 
four relatively course stages and does not give information about the location and 
depth of the defect(s). It is time-consuming and impractical for day to day analysis of 
every VF test results. Another limitation is this system may suggest a significant 
deterioration when in fact none has occurred (Susanna Jr and Vessani, 2009). 
 
1.3.4 Factors affecting visual field progression  
Age as a risk factor for glaucoma progression has been confirmed by many clinical 
trials (Gordon et al., 2002; Leske et al., 2003; Musch et al., 2009). Not all patients 
with elevated IOP is considered to have glaucoma (Linner & Stromberg, 1964; Armaly 
MF, 1969; Spaeth GL, 1994) and around one-third or more of those with glaucomatous 
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optic discs changes and visual field (VF) defects did not have elevated IOP (Hollows 
& Graham, 1966; Shiose Y, 1983; Spaeth GL, 1994). Once diagnosed as glaucoma, 
elevated IOP during follow up was a strong factor for glaucoma progression with the 
hazard ratio increasing by 11% for every 1 mmHg of higher IOP in Early Manifest 
Glaucoma Trial study (EMGT) (Heijl et al., 2002).  Large IOP fluctuations may be 
associated with disease progression in PACG eyes (Gazzard et al., 2003; Tan et al., 
2015).  
 
In a 5 year observational study done in India, it showed that the progression rate and 
mean IOP was higher in patients who did not receive laser peripheral iridotomy 
(Thomas et al., 2003). While other similar study done elsewhere predicted that laser 
peripheral iridotomy can prevent progression as it can contribute to lower/controlled 
IOP at an initial stage (Nolan et al., 2000). Some studies predicted laser peripheral 
iridotomy is not enough, chronic angle closure glaucoma often requires further surgical 
interventions (Alsagoff et al., 2000; Nolan et al., 2000). 
 
Female gender, migraine and disc haemorrhage have also reported to be the risk factors 
associated with progression in normal tension glaucoma (NTG) (Drance et al., 2001; 
Skaat et al., 2016). In EMGT study, disc haemorrhage and thinner central cornea 
thickness (CCT) are also significant glaucoma progression factors (Leske et al., 2007). 
On the other hand, longer follow up and a higher number of glaucoma interventions 
are associated with visual field progression in AGIS study (Nouri-Mahdavi et al., 
2004) 
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1.4  GENETICS 
Advances in glaucoma genetics have increased our knowledge on genetic factors 
contributing to the development of most types of glaucoma. Study of genetics has 
evolved ever since Human Genome Project was completed in 2003 and the 
International HapMap Project in 2005. This became a platform for researches to look 
into genetic contributions to common diseases. The project is a research tool with 
computerised databases containing reference human genome sequence and a map of 
human genetic variation that allow any researchers to analyze whole-genome samples 
for genetic variations that contribute to the onset of a disease (Bush and Moore, 2012). 
A major outcome of the project is through genome wide association study (GWAS),. 
This method searches the genome for small variations, called single nucleotide 
polymorphisms or SNPs (pronounced "snips"), that occur more frequently in people 
with a particular disease than in people without the disease (Hirschhorn and Daly, 
2005). Each study can look at hundreds or thousands of SNPs at the same time. 
Researchers use data from this type of study to pinpoint genes that may contribute to 
a person’s risk of developing a certain disease. An archive of data from genome-wide 
association studies on a variety of diseases and conditions already can be accessed 
through an NCBI Web site, called the Database of Genotype and Phenotype (dbGaP) 
located at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gap. 
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1.4.1    Genetics in glaucoma  
Mostly, patients exhibit autosomal dominant or autosomal recessive inheritance, for 
early onset disease (less than age 35). Whereas adult-onset glaucoma has complex 
inheritance pattern due to multiple genetic and/or environmental risk factors 
influences. Some of the discoveries made; for example, two genes CYP1B1 coding for 
cytochrome P450 1B1 and LTBP2 has been discovered to cause congenital glaucoma 
(Lim et al., 2013). Axenfeld-Rieger syndrome, aniridia, and glaucoma associated with 
anterior segment dysgenesis are caused by mutations in PITX2, PAX6, and FOXC1, 
respectively (Lee et al., 2008; Reis et al., 2012). To date, POAG has been linked to 20 
genetic loci but only 3 causative genes were identified from these loci; myocilin 
(MYOC), optineurin (OPTN) and WD repeat domain 36 (WDR36) (Fan et al., 2006). 
Whereas PACG related studies conducted within Asian populations identified 
significant polymorphisms with the PLEKHA7 and COL11A1 genes and an intergenic 
region between PCMTD1 and ST18 on chromosome 8q (Vithana et al., 2012). KALRN 
gene was identified as susceptible genetic marker for progression of POAG in Malay 
patients.  KALRN gene plays important role in Rho associated protein kinase (ROCK) 
pathway. ROCK pathway is involved in aqueous humor drainage, improvement in 
retinal circulation and potential neuroprotective effect (Inoue and Tanihara, 2013; 
Wang and Chang, 2014). Perhaps, potentially KALRN gene may also affect the risk 
of progression in PACG. To date, no study conducted involving KALRN gene and 
PACG. 
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1.4.2    Genetics in PACG  
A gene is a sequence of deoxyribonucleic acid (DNA) that carries the information 
representing a protein (Lewin, 1987). The building blocks of DNA are nucleotides that 
are arranged in pairs and form a double helix. The 23 pairs of chromosomes that 
embody the human genome are comprised of approximately 3.12 billion sequence 
nucleotide pairs. These nucleotides are arranged in highly conserved sequence. It is 
estimated that the sequence differences between any human are less than 1%. 
 
The most common sequence difference observed in humans is called single nucleotide 
polymorphism (SNP). This is a sequence change that alters a single nucleotide pair in 
a sequence of DNA, which can code for a change in structure or expression of a 
protein. These change can be beneficial or have a negative effect. Thus polymorphism 
is any genetic variation that is present within a population that occurs with a relatively 
high frequency, usually considered more than 1% (Karki et al., 2015). Most 
polymorphism does not cause an identifiable change in the organism in which it 
occurs. However, it may alter disease susceptibility and drug response. 
 
The earliest PACG study was done by Tornquist (1953). He suggested that angle 
closure glaucoma was transmitted by a single dominant gene. Unfortunately, studies 
could not prove the hypothesis (Tornquist, 1953). However, the genetic link to PACG 
is more of associated with single nucleotide polymorphism (SNP). The relationship 
between SNPs of the extracellular matrix, matrix metalloproteases (MMP) and PACG 
was studied by Jang and colleagues. They concluded that SNP of the MMP gene is 
likely to be associated with acute PACG (Wang et al., 2006). More studies have been 
 16 
conducted to understand the molecular basis of this major cause of blindness. Recent 
discoveries of SNPs which were significantly related to PACG were PLEKHA7, 
ABCC5 and COL11A1 (Khor et al., 2016; Nongpiur et al., 2014; Vithana et al., 2012). 
So far, only POAG related genetic study manage to show strong association with 
disease progression (Trikha et al., 2015). 
 
1.4.2.1 PLEKHA7 
PLEKHA 7 (Pleckstrin homology domain-containing family A member 7) 
 
Figure1: location of the gene in chromosome 11 (11p15.2-p15.1) 
 
The function of PLEKHA7 was reported to be a component of the zonula adherens, a 
specialised cadherin-based cell–cell junction (Meng et al., 2008). In humans, the gene 
is mapped to chromosome 11p15.1. PLEKHA gene has been associated with many 
diseases in relation to the eye, notably age related maculopathy and angle closure 
glaucoma (Connell et al., 2009; Vithana et al., 2012; Wei et al., 2014).  
 
1.4.2.2 ABCC5 
ABCC5 (ATP-binding cassette, subfamily C, member 5), located in chromosome 
3q27.1. The protein coded by this gene involved in multi-drug resistance, cellular and 
export mechanism (Wijnholds et al., 2000). Studies speculated that this protein 
probably involved in resistance to thiopurines in acute lymphoblastic leukaemia and 
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antiretroviral nucleoside analogues in HIV-infected patients (Reid et al., 2003). 
ABCC5 was also shown to have a significant association with PACG, as it has a strong 
contribution to anterior chamber depth (Nongpiur et al., 2014). 
 
 
1.4.2.3 KALRN 
KALIRIN; KALRN is a multidomain guanine nucleotide exchange factor (GEF) for 
small GTP-binding proteins of the Rho family (McPherson et al., 2002). McPherson 
also determined that the KALRN gene contains 60 coding exons and spans more than 
600 kb. Intron 10 contains an internal start site from which the delta-kalirin transcripts 
initiate. KALRN gene at chromosome 3q13 in a fine-mapping study of the chromosome 
3q region linked to early-onset coronary artery disease (Wang et al., 2007). KALRN 
gene was found to involve in the Rho Guanosisne triphosphatase (GTPase) signal 
transduction pathway or also known as Rho-kinase (ROCK) pathway that influences 
cellular activity in angle structure (Somlyo et al., 2000; Wang et al., 2007). This 
pathway influences the function of trabecular meshwork. PACG is closely related to 
trabecular meshwork and angle structure changes.  However, there was no available 
study assessing the role of KALRN gene in PACG. 
 
1.5     RATIONALE OF THE STUDY 
Glaucoma is the leading cause of a complex and irreversible blindness worldwide. It 
is a global phenomenon which is expected to increase in the future. The severity of 
bilateral blindness in PACG exceeds that of POAG with the majority of PACG found 
in Asia due to a higher prevalence among Asians. IOP remains the only modifiable 
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risk factors, hence in recent years; there is an increased interest to identify risk factors, 
pathophysiology and preventive measures to halt the progression of glaucoma. There 
are several susceptible genetic markers for PACG identified through GWAS. 
However, there was no fruitful finding of genetic markers for progression of PACG. 
To the best of our knowledge, there is no study that evaluates the relationship between 
PACG related SNPs like ABCC5 and PLEKHA7 with disease progression in Malay 
patients. KALRN gene was identified as susceptible genetic marker for progression of 
POAG in Malay patients. KALRN gene has been linked to ROCK pathway that 
influences cellular activity involving trabecular meshwork, aqueous humor drainage 
and retinal circulation. In fact, PACG is closely related to trabecular meshwork and 
angle structure activities. However, no study conducted involving KALRN gene and 
PACG. 
 
Many studies regarding glaucoma have been conducted around Asia and other 
ethnicity, but studies on Malays, which represents 5% of the world population, is 
disappointedly lacking. The knowledge on genetics that affects the risk and 
progression of PACG may provide immense insight for possible primary intervention 
and future management of PACG. Genetics screening for markers associated with 
progression is important to high risk individuals; positive family history or with ocular 
risk factors for early intervention and prevention of blindness among glaucoma 
patients. Prevention of progression may also reduce the financial burden of treatment.  
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